A novel pathway regulating cytokine production and asthma development

调节细胞因子产生和哮喘发展的新途径

基本信息

  • 批准号:
    7356481
  • 负责人:
  • 金额:
    $ 23.4万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-05-15 至 2011-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION: Cytokines produced by CD4+ T lymphocytes play essential roles in host adaptive immune responses and are involved in the development of allergic diseases including asthma. Our understanding of the pathways regulating cytokine production in CD4+ T lymphocytes remains incomplete. We have identified a novel pathway regulating cytokine production in CD4+ T cells using molecules that are thought to be primarily involved in neuronal cell function and pathogenesis of Alzheimer's disease. We show that CD4+ T cells lacking the extracellular matrix (ECM) protein F-spondin or its receptor apoE receptor 2 (ApoER2) exhibit defective cytokine production, and asthma development is attenuated in mice lacking F-spondin. Our overall hypothesis is that F-spondin and its receptors ApoER2 and amyloid-2 precursor protein (APP) constitute a novel ligand-receptor pairs whose interaction on the CD4+ T cell surface provides a critical signal to initiate cytokine production. To test this hypothesis, we propose two specific aims: 1. To establish the mechanisms by which F-spondin regulates CD4+ T lymphocyte cytokine production. 2. To examine the signaling pathway mediated by ApoER2 and APP in CD4+ T lymphocyte cytokine production. Results from these studies will not only provide important mechanistic insights into the regulation of CD4+ T lymphocyte cytokine production and asthma development, but also may lead to discoveries of novel drug targets for asthma treatment. Given the current effort by industry and academia to develop Alzheimer's disease treatments, our proposed research may be able to redirect the drugs developed for Alzheimer's disease into asthma treatment. Project Narrative Cytokines produced by CD4+ T lymphocytes are involved in the development of allergic diseases including asthma. Our understanding of the pathways regulating cytokine production and asthma development remains incomplete. Investigation of the pathways regulating cytokine production and asthma development will lead to new discoveries that will help drug designs for asthma treatment. Our recent work has identified a novel pathway regulating cytokine production in CD4+ T cells and asthma development in mice by molecules that are thought to be primarily involved in neuronal cell function and pathogenesis of Alzheimer's disease. Given the current effort in the development of Alzheimer's disease treatment by industry and academia, our proposed research may be able to redirect the drugs developed for Alzheimer's disease into asthma treatment.
产品说明:由CD 4 + T淋巴细胞产生的细胞因子在宿主适应性免疫应答中起重要作用,并参与包括哮喘在内的过敏性疾病的发展。我们对调节CD 4 + T淋巴细胞中细胞因子产生的途径的理解仍然不完整。我们已经确定了一种新的途径,调节细胞因子的产生在CD 4 + T细胞使用的分子,被认为是主要参与神经元细胞功能和阿尔茨海默病的发病机制。我们发现,CD 4 + T细胞缺乏细胞外基质(ECM)蛋白F-spondin或其受体apoE受体2(ApoER 2)表现出缺陷的细胞因子的生产,和哮喘的发展是在小鼠缺乏F-spondin衰减。我们的总体假设是,F-spondin及其受体ApoER 2和淀粉样蛋白-2前体蛋白(APP)构成了一种新的配体-受体对,其在CD 4 + T细胞表面的相互作用提供了启动细胞因子产生的关键信号。为了验证这一假设,我们提出了两个具体目标:1。目的:探讨F-spondin调节CD 4 + T淋巴细胞产生细胞因子的机制。2.探讨ApoER 2和APP介导的CD 4 + T淋巴细胞产生细胞因子的信号通路。这些研究结果不仅将为CD 4 + T淋巴细胞细胞因子产生和哮喘发展的调节提供重要的机制见解,而且可能导致发现新的哮喘治疗药物靶点。鉴于目前工业界和学术界正在努力开发阿尔茨海默病的治疗方法,我们提出的研究可能能够将为阿尔茨海默病开发的药物重新导向哮喘治疗。项目叙述 由CD 4 + T淋巴细胞产生的细胞因子参与包括哮喘在内的过敏性疾病的发展。我们对调节细胞因子产生和哮喘发展的途径的理解仍然不完全。对调节细胞因子产生和哮喘发展的途径的研究将导致新的发现,这将有助于哮喘治疗药物的设计。我们最近的工作已经确定了一种新的途径,通过被认为主要参与神经元细胞功能和阿尔茨海默病发病机制的分子调节小鼠CD 4 + T细胞中细胞因子的产生和哮喘的发展。鉴于目前工业界和学术界在阿尔茨海默病治疗方面的努力,我们提出的研究可能能够将为阿尔茨海默病开发的药物重新定向到哮喘治疗中。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

You-Wen He其他文献

You-Wen He的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('You-Wen He', 18)}}的其他基金

The impact of genetic diversity among Akkermansia strains on the effectivenes of immune checkpoint inhibitors in cancer immunotherapies
阿克曼氏菌菌株遗传多样性对癌症免疫治疗中免疫检查点抑制剂有效性的影响
  • 批准号:
    10115682
  • 财政年份:
    2020
  • 资助金额:
    $ 23.4万
  • 项目类别:
Autophagy in T lymphocyte function
T 淋巴细胞功能中的自噬
  • 批准号:
    7812172
  • 财政年份:
    2009
  • 资助金额:
    $ 23.4万
  • 项目类别:
A novel pathway regulating cytokine production and asthma development
调节细胞因子产生和哮喘发展的新途径
  • 批准号:
    7843494
  • 财政年份:
    2009
  • 资助金额:
    $ 23.4万
  • 项目类别:
Autophagy in T lymphocyte function
T 淋巴细胞功能中的自噬
  • 批准号:
    8461210
  • 财政年份:
    2009
  • 资助金额:
    $ 23.4万
  • 项目类别:
Autophagy in T lymphocyte function
T 淋巴细胞功能中的自噬
  • 批准号:
    8050675
  • 财政年份:
    2009
  • 资助金额:
    $ 23.4万
  • 项目类别:
Autophagy in T lymphocyte function
T 淋巴细胞功能中的自噬
  • 批准号:
    8260354
  • 财政年份:
    2009
  • 资助金额:
    $ 23.4万
  • 项目类别:
Autophagy in T lymphocyte function
T 淋巴细胞功能中的自噬
  • 批准号:
    7590040
  • 财政年份:
    2009
  • 资助金额:
    $ 23.4万
  • 项目类别:
BcI-2 family in T lymphocyte homeostasis
Bcl-2 家族在 T 淋巴细胞稳态中的作用
  • 批准号:
    8389558
  • 财政年份:
    2008
  • 资助金额:
    $ 23.4万
  • 项目类别:
Function of thymic epithelial cells in T lymphocyte maturation
胸腺上皮细胞在T淋巴细胞成熟中的功能
  • 批准号:
    7686243
  • 财政年份:
    2008
  • 资助金额:
    $ 23.4万
  • 项目类别:
BcI-2 family in T lymphocyte homeostasis
Bcl-2 家族在 T 淋巴细胞稳态中的作用
  • 批准号:
    7580414
  • 财政年份:
    2008
  • 资助金额:
    $ 23.4万
  • 项目类别:

相似海外基金

Elucidation of the mechanisms of clothing-induced allergic symptoms and quantification of itching
阐明衣服引起的过敏症状的机制和瘙痒的量化
  • 批准号:
    23H00914
  • 财政年份:
    2023
  • 资助金额:
    $ 23.4万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mechanism of Retinal Choroidal Inflammation in Chronic Severe Allergic Conjunctivitis
慢性重症过敏性结膜炎视网膜脉络膜炎症机制
  • 批准号:
    23K15918
  • 财政年份:
    2023
  • 资助金额:
    $ 23.4万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Gut Microbial Factors in Farming Lifestyle and Allergic Sensitization
农业生活方式和过敏致敏中的肠道微生物因素
  • 批准号:
    10633368
  • 财政年份:
    2023
  • 资助金额:
    $ 23.4万
  • 项目类别:
Role of Skin Barrier and Immune Alterations in Allergic Sensitization
皮肤屏障和免疫改变在过敏性致敏中的作用
  • 批准号:
    10633370
  • 财政年份:
    2023
  • 资助金额:
    $ 23.4万
  • 项目类别:
Lung resident Treg suppression of Th2 resident memory T cells in allergic asthma
过敏性哮喘中肺常驻 Treg 对 Th2 常驻记忆 T 细胞的抑制
  • 批准号:
    10664599
  • 财政年份:
    2023
  • 资助金额:
    $ 23.4万
  • 项目类别:
Elucidation of the mechanisms by which paired immune receptors recognize their ligands and development of treatments for allergic and inflammatory diseases
阐明配对免疫受体识别其配体的机制并开发过敏性和炎症性疾病的治疗方法
  • 批准号:
    23H02946
  • 财政年份:
    2023
  • 资助金额:
    $ 23.4万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Genetic analysis of the pathogenesis of atopic dermatitis focusing on the allergic sensitivity of NC mice.
以NC小鼠过敏敏感性为重点的特应性皮炎发病机制的遗传分析。
  • 批准号:
    23K05600
  • 财政年份:
    2023
  • 资助金额:
    $ 23.4万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Relationship between changes in intestinal microflora and anti-allergic effects caused by ingestion of koji-fermented soybeans
摄入曲发酵大豆引起的肠道菌群变化与抗过敏作用的关系
  • 批准号:
    23K02043
  • 财政年份:
    2023
  • 资助金额:
    $ 23.4万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of a highly sensitive and specific POCT testing asthma triggering allergic IgE
开发高度敏感和特异的 POCT 测试哮喘触发过敏性 IgE
  • 批准号:
    10600767
  • 财政年份:
    2023
  • 资助金额:
    $ 23.4万
  • 项目类别:
3D genome organization of the Ets1-Fli1 locus controls allergic responses
Ets1-Fli1 基因座的 3D 基因组组织控制过敏反应
  • 批准号:
    10654172
  • 财政年份:
    2023
  • 资助金额:
    $ 23.4万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了